SBM Stock Overview
Sirona Biochem Corp., a cosmetic ingredient and drug discovery company, develops and sells cosmetic and pharmaceutical active ingredients in Canada and France.
Sirona Biochem Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||CA$0.18|
|52 Week High||CA$0.35|
|52 Week Low||CA$0.14|
|1 Month Change||-11.91%|
|3 Month Change||-7.50%|
|1 Year Change||-11.91%|
|3 Year Change||-58.89%|
|5 Year Change||27.59%|
|Change since IPO||68.18%|
Recent News & Updates
|SBM||CA Biotechs||CA Market|
Return vs Industry: SBM underperformed the Canadian Biotechs industry which returned 11.1% over the past year.
Return vs Market: SBM underperformed the Canadian Market which returned 0.7% over the past year.
|SBM Average Weekly Movement||13.1%|
|Biotechs Industry Average Movement||13.0%|
|Market Average Movement||10.6%|
|10% most volatile stocks in CA Market||18.9%|
|10% least volatile stocks in CA Market||4.3%|
Stable Share Price: SBM is not significantly more volatile than the rest of Canadian stocks over the past 3 months, typically moving +/- 13% a week.
Volatility Over Time: SBM's weekly volatility (13%) has been stable over the past year.
About the Company
Sirona Biochem Corp., a cosmetic ingredient and drug discovery company, develops and sells cosmetic and pharmaceutical active ingredients in Canada and France. Its programs include cosmetic skin lightener and diabetes drug; and other projects include the development of an anti-aging/cell protection library, novel anti-wrinkle compound, and anti-viral program. The company was formerly known as High Rider Capital Inc. and changed its name to Sirona Biochem Corp. in May 2009.
Sirona Biochem Fundamentals Summary
|SBM fundamental statistics|
Is SBM overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|SBM income statement (TTM)|
|Cost of Revenue||CA$68.77k|
Last Reported Earnings
Apr 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.014|
|Net Profit Margin||-6,119.70%|
How did SBM perform over the long term?See historical performance and comparison
Is SBM undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 1/6
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for SBM?
Other financial metrics that can be useful for relative valuation.
|What is SBM's n/a Ratio?|
Price to Book Ratio vs Peers
How does SBM's PB Ratio compare to its peers?
|SBM PB Ratio vs Peers|
|Company||PB||Estimated Growth||Market Cap|
COV Covalon Technologies
ACOG Alpha Cognition
DTC Defence Therapeutics
GLAB Gemina Laboratories
SBM Sirona Biochem
Price-To-Book vs Peers: SBM is good value based on its Price-To-Book Ratio (53.5x) compared to the peer average (64.6x).
Price to Earnings Ratio vs Industry
How does SBM's PE Ratio compare vs other companies in the CA Biotechs Industry?
Price-To-Book vs Industry: SBM is expensive based on its Price-To-Book Ratio (53.5x) compared to the Canadian Biotechs industry average (2.7x)
Price to Book Ratio vs Fair Ratio
What is SBM's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PB Ratio||53.5x|
|Fair PB Ratio||n/a|
Price-To-Book vs Fair Ratio: Insufficient data to calculate SBM's Price-To-Book Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of SBM when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate SBM's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate SBM's fair value for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
How is Sirona Biochem forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Sirona Biochem has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Discover growth companies
- Examine Sirona Biochem's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
- Sirona Biochem competitive advantages and company strategy can generally be found in its financial reports archived here.
How has Sirona Biochem performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: SBM is currently unprofitable.
Growing Profit Margin: SBM is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: SBM is unprofitable, and losses have increased over the past 5 years at a rate of 1.1% per year.
Accelerating Growth: Unable to compare SBM's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SBM is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (29.2%).
Return on Equity
High ROE: SBM has a negative Return on Equity (-413.97%), as it is currently unprofitable.
Discover strong past performing companies
How is Sirona Biochem's financial position?
Financial Health Score4/6
Financial Health Score 4/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: SBM's short term assets (CA$2.0M) exceed its short term liabilities (CA$743.3K).
Long Term Liabilities: SBM's short term assets (CA$2.0M) exceed its long term liabilities (CA$411.7K).
Debt to Equity History and Analysis
Debt Level: SBM has more cash than its total debt.
Reducing Debt: SBM's debt to equity ratio has reduced from 414.5% to 67.3% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: SBM has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: SBM has less than a year of cash runway if free cash flow continues to reduce at historical rates of 2% each year
Discover healthy companies
What is Sirona Biochem current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate SBM's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate SBM's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if SBM's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if SBM's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as SBM has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Howard Verrico (61 yo)
Dr. Howard J. Verrico, M.D., Ph D, is the Founder of Sirona Biochem Corp., has been Chief Executive Officer since June 18, 2014 and serves as its Secretary. Dr. Verrico served as the Chief Executive Office...
CEO Compensation Analysis
Compensation vs Market: Howard's total compensation ($USD125.03K) is below average for companies of similar size in the Canadian market ($USD186.79K).
Compensation vs Earnings: Howard's compensation has been consistent with company performance over the past year.
Experienced Management: SBM's management team is seasoned and experienced (10.4 years average tenure).
Experienced Board: SBM's board of directors are seasoned and experienced ( 12.2 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 9.3%.
Sirona Biochem Corp.'s employee growth, exchange listings and data sources
- Name: Sirona Biochem Corp.
- Ticker: SBM
- Exchange: TSXV
- Founded: 2006
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: CA$46.570m
- Shares outstanding: 251.73m
- Website: https://www.sironabiochem.com
- Sirona Biochem Corp.
- 595 Burrard Street
- British Columbia
- V7X 1L4
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/08/15 00:00|
|End of Day Share Price||2022/08/15 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.